# A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants

> **NCT05105607** · PHASE1 · COMPLETED · sponsor: **Ashvattha Therapeutics, Inc.** · enrollment: 16 (actual)

## Conditions studied

- Neovascular Age-related Macular Degeneration
- Diabetic Macular Edema

## Interventions

- **DRUG:** D-4517.2

## Key facts

- **NCT ID:** NCT05105607
- **Lead sponsor:** Ashvattha Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-11
- **Primary completion:** 2022-08-31
- **Final completion:** 2022-08-31
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2022-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05105607

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05105607, "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of D-4517.2 After Subcutaneous Administration in Healthy Participants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05105607. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*